Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 130, Issue 17
October 26 2017
Issue Cover

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
Ruxolitinib in ET: not all MPN are equal
Clinical Trials & Observations
Guido Finazzi
View Articletitled, Ruxolitinib in ET: not all MPN are equal
INSIDE BLOOD COMMENTARY
Finding active LCH cells in the blood
Oussama Abla
View Articletitled, Finding active LCH cells in the blood
INSIDE BLOOD COMMENTARY
TP53 mutations in MCL: more therapy is not better
Jonathon B. Cohen
View Articletitled, <em>TP53</em> mutations in MCL: more therapy is not better
INSIDE BLOOD COMMENTARY
A scale of “bad” co-mutations in NPM1-driven AML
Brunangelo Falini,Paolo Sportoletti
View Articletitled, A scale of “bad” co-mutations in <em>NPM1</em>-driven AML

PERSPECTIVES

The potential for chemotherapy-free strategies in mantle cell lymphoma
Clinical Trials & Observations
Peter Martin,Jia Ruan,John P. Leonard
View Articletitled, The potential for chemotherapy-free strategies in mantle cell lymphoma

CLINICAL TRIALS AND OBSERVATIONS

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Clinical Trials & Observations
Claire N. Harrison,Adam J. Mead,Anesh Panchal,Sonia Fox,Christina Yap,Emmanouela Gbandi,Aimee Houlton,Samah Alimam,Joanne Ewing,Marion Wood,Frederick Chen,Jason Coppell,Nicki Panoskaltsis,Steven Knapper,Sahra Ali,Angela Hamblin,Robyn Scherber,Amylou C. Dueck,Nicholas C. P. Cross,Ruben Mesa,Mary Frances McMullin
View Articletitled, Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

CD207+CD1a+ cells circulate in pediatric patients with active Langerhans cell histiocytosis
Brief Report
Eugenio Antonio Carrera Silva,Wanda Nowak,Licina Tessone,Cinthia Mariel Olexen,Juan Manuel Ortiz Wilczyñski,Ivana Gisele Estecho,Graciela Elena,Andrea Emilse Errasti,Diego Alfredo Rosso
View Articletitled, CD207<sup>+</sup>CD1a<sup>+</sup> cells circulate in pediatric patients with active Langerhans cell histiocytosis
Supplemental data

LYMPHOID NEOPLASIA

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Clinical Trials & Observations
Christian W. Eskelund,Christina Dahl,Jakob W. Hansen,Maj Westman,Arne Kolstad,Lone B. Pedersen,Carmen P. Montano-Almendras,Simon Husby,Catja Freiburghaus,Sara Ek,Anja Pedersen,Carsten Niemann,Riikka Räty,Peter Brown,Christian H. Geisler,Mette K. Andersen,Per Guldberg,Mats Jerkeman,Kirsten Grønbæk
View Articletitled, <em>TP53</em> mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Supplemental data

MYELOID NEOPLASIA

Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia
Oliver M. Dovey,Jonathan L. Cooper,Annalisa Mupo,Carolyn S. Grove,Claire Lynn,Nathalie Conte,Robert M. Andrews,Suruchi Pacharne,Konstantinos Tzelepis,M. S. Vijayabaskar,Paul Green,Roland Rad,Mark Arends,Penny Wright,Kosuke Yusa,Allan Bradley,Ignacio Varela,George S. Vassiliou
View Articletitled, Molecular synergy underlies the co-occurrence patterns and phenotype of <em>NPM1</em>-mutant acute myeloid leukemia
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator
Evangelia Vlachodimitropoulou,Yu-Lin Chen,Maciej Garbowski,Pimpisid Koonyosying,Bethan Psaila,Martha Sola-Visner,Nichola Cooper,Robert Hider,John Porter
View Articletitled, Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator
Supplemental data
The actin-binding protein profilin 2 is a novel regulator of iron homeostasis
Sara Luscieti,Bruno Galy,Lucia Gutierrez,Michael Reinke,Jorge Couso,Maya Shvartsman,Antonio Di Pascale,Walter Witke,Matthias W. Hentze,Pietro Pilo Boyl,Mayka Sanchez
View Articletitled, The actin-binding protein profilin 2 is a novel regulator of iron homeostasis
Supplemental data

TRANSPLANTATION

At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT
Brief Report
Courtney D. Fitzhugh,Stefan Cordes,Tiffani Taylor,Wynona Coles,Katherine Roskom,Mary Link,Matthew M. Hsieh,John F. Tisdale
View Articletitled, At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT
Supplemental data

LETTERS TO BLOOD

WIP deficiency severely affects human lymphocyte architecture during migration and synapse assembly
Laurène Pfajfer,Markus G. Seidel,Raïssa Houmadi,Javier Rey-Barroso,Tatjana Hirschmugl,Elisabeth Salzer,Inés María Antón,Christian Urban,Wolfgang Schwinger,Kaan Boztug,Loïc Dupré
View Articletitled, WIP deficiency severely affects human lymphocyte architecture during migration and synapse assembly
Supplemental data
Origins of myelodysplastic syndromes after aplastic anemia
Eiju Negoro,Yasunobu Nagata,Michael J. Clemente,Naoko Hosono,Wenyi Shen,Aziz Nazha,Tetsuichi Yoshizato,Cassandra Hirsch,Bartlomiej Przychodzen,Reda Z. Mahfouz,Teodora Kuzmanovic,Mikkael A. Sekeres,Hideki Makishima,Seishi Ogawa,Jaroslaw P. Maciejewski
View Articletitled, Origins of myelodysplastic syndromes after aplastic anemia
Supplemental data

BLOOD WORK

Atypical monoblasts with micronuclei
Sylvie Bouvier,Mélanie Martin
View Articletitled, Atypical monoblasts with micronuclei
All Issues

Advertisement intended for health care professionals

Time for a new prognostic score in CLL?
Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113(18):4341-4351.
Garcia E, Horowitz AM, Franklin K, Mader M, Kaur S. Outcomes of veterans with FMS-like tyrosine kinase 3 mutated (mFLT3) acute myeloid leukemia (AML) treated with novel FLT3 inhibitors (FLT3i) within the Veterans Health Administration (VHA) [abstract]. Blood. 2023;142(suppl 1):7414.
Soluble Glycoprotein VI Predicts Abdominal Aortic Aneurysm Growth Rate and is a Novel Therapeutic Target
Murine models of erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxine

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals